UNASSIGNED: A better understanding of the relationship between @entity463 molecular subtypes and radio-chemotherapy is needed for the development of individualized strategies. In this study, we aimed to assess whether non-homologous end-joining (NHEJ) protein expression is associated and could predict responses to treatment of @entity361 ( @entity361 ) and proneural (PN) subtypes. @entity5 from 122 @entity1 with a @entity463 treated at the University Hospital of Poitiers between 2002-2013 by an association of radiotherapy and @entity2903 were collected. Among these @entity5 , 80 were suitable for in situ analysis and were included in TissueMicroArray. The expression of @entity10322 , @entity10320 , @entity10321 and @entity1759 , @entity14382 (respectively surrogate markers of @entity361 and PN subtypes) were evaluated by immunohistochemistry. The median survival of @entity1 with high and low @entity1759 expression was 11.9 months (95% CI 7.7-14) and 19.1 months (95% CI 15.2-22.4) respectively (p   =   0.008). Median survival of @entity1 with high and low @entity10322 levels was 20.0 months (95% CI 15.2-25.3) and 12.9 months (95% CI 9.9-19.5) respectively (p   =   0.036). High levels of @entity14382 , @entity10320 and @entity10321 tended to be associated with better overall survival but no significant differences were found. Overall survival of class I @entity1 ( @entity1759 + and @entity10322 +) was longer than class II ( @entity1759 + and @entity10322 - or @entity1759 - and @entity10322 +) and class III ( @entity1759 - and @entity10322 -), (p   =   0.005 and 0.003 respectively). High levels of @entity1759 and @entity10322 are associated with a better survival and better response to radiotherapy and @entity2903 and could establish prognosis classes by predicting survival and response to therapy for GBMs @entity1 .

Mesenchymal subtype of @entity463 with high XXXX expression is associated with better response to radiotherapy and @entity2903 .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity14382 :: ('10215', 'Gene') :: ['Olig2'] @entity5 :: ('MESH:D009369', 'Disease') :: ['Tumors', 'tumors'] @entity10321 :: ('7520', 'Gene') :: ['Ku80'] @entity1759 :: ('960', 'Gene') :: ['CD44'] @entity10320 :: ('2547', 'Gene') :: ['Ku70'] @entity2903 :: ('MESH:C047246', 'Chemical') :: ['temozolomide'] @entity361 :: ('MESH:C535700', 'Disease') :: ['MES', 'mesenchymal'] @entity10322 :: ('5591', 'Gene') :: ['DNA-PK', 'DNA-PKcs'] @entity463 :: ('MESH:D005909', 'Disease') :: ['glioblastomas', 'glioblastoma']
@entity10322 :: (5591,Gene) :: ['DNA-PKcs']
